Summary

Who does this guideline apply to?

This guideline applies to infants and children.

Who is the audience for this guideline?

This guideline is for health professionals and those who provide healthcare in environments where equipment and drugs are available.

Recommendations

1. This guideline provides detailed advice regarding the place of drugs and intravenous fluids in the management of cardiac arrest in infants and children.
1 Introduction

All intravenous (IV) and intraosseous (IO) drugs should be flushed with small boluses of 0.9% sodium chloride or 5% glucose (for amiodarone). This ensures that the drugs enter the circulation and prevents precipitation or inactivation as occurs when sodium bicarbonate mixes with calcium, or when sodium bicarbonate mixes with adrenaline (epinephrine). Medications used in paediatric CPR are listed alphabetically. See Guideline 12.5 for use in treatment of specific dysrhythmias.

2 Adrenaline (epinephrine)

Both alpha and beta effects of adrenaline (epinephrine) are useful in management of cardiopulmonary resuscitation. Alpha vasoconstrictor effects diverts blood to the cerebral and coronary circulation and can facilitate defibrillation while beta effects are chronotropic and inotropic. Although it is uncertain if survival or neurological outcome are improved by its use, it is reasonable to employ adrenaline (epinephrine) in standard dosing to achieve return of spontaneous circulation. (CoSTR 2015, Values and Preferences)

The optimal dose and frequency of administration of adrenaline (epinephrine) in children are unknown. The initial and any subsequent dose by the intravenous or intraosseous route is 10mcg/kg, (10 micrograms/kg) with a maximum single dose of 1mg. [Class A; Expert Consensus Opinion]. In special circumstances such as beta-blocker use or poisoning, larger doses may be used but are otherwise not recommended.

Higher and excessive doses of adrenaline (epinephrine) may have significant complications of severe vasoconstriction, hypertension and tachydysrhythmias. In the treatment of in-hospital paediatric arrest, administration of 100 mcg/kg after an initial 10 mcg/kg was associated with lower short-term survival than administration of first and subsequent doses of 10 mcg/kg [LOE II].

The systemic absorption of adrenaline (epinephrine) from endotracheal tube (ETT) administration is variable. Although unproven to be the optimal dose, 100mcg/kg is the accepted paediatric endotracheal ETT dose [Class A; Expert Consensus Opinion].

Adrenaline (epinephrine) is used to treat asystole, severe bradycardia, ventricular fibrillation and electromechanical dissociation. It should be given intravenously or intraosseously at intervals of 4 minutes or every second loop (Guideline 12.3) [Class A, Expert Consensus Opinion]. Instead of repeated bolus doses, a continuous infusion of approximately 0.1 – 0.2 mcg/kg/min or higher doses may be given – preferably into a large vein to avoid extravasation necrosis.

3 Amiodarone

Amiodarone is an antiarrhythmic drug with complex pharmacokinetics and pharmacodynamics. It may be used for shock-resistant ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT). The initial paediatric dose for shock-resistant
ventricular fibrillation and pulseless ventricular tachycardia is a bolus of 5 mg/kg, which may be repeated. [Class A; Expert Consensus Opinion].

There is limited evidence that lidocaine (lignocaine) may increase rates of ROSC vs. amiodarone, and that amiodarone may increase rates of survival to hospital admission vs. lidocaine (lignocaine). Studies have failed to show an association between the use of either lidocaine (lignocaine) or amiodarone and survival to hospital discharge. We suggest that either amiodarone or lidocaine (lignocaine) may be used for the treatment of pediatric shock–resistant VF/pVT² (CoSTR 2015, weak recommendation, very low quality evidence).

Amiodarone has become the standard antiarrhythmic drug for use in paediatric shock resistant VF and pVT, and it is reasonable for this to continue in the absence of strong evidence to change practice (Expert Consensus Opinion).

In children, amiodarone can be used to successfully treat a wide range of other tachydysrhythmias, notably atrial tachycardias, (recurrent) supraventricular tachycardia, pulsatile ventricular tachycardia, junctional ectopic tachycardia [Class A; LOE III-3] and wide QRS-complex tachycardia [Class A; Expert Consensus Opinion] (Refer Guideline 12.5).

4 Atropine (atropine sulfate monohydrate)

Parasympathetic cardiac blockade with atropine may be indicated if bradycardia is caused by vagal stimulation or cholinergic drug toxicity¹. It is uncertain if atropine reduces the incidence of bradycardia or cardiac arrest on emergency tracheal intubation or if atropine leads to increased survival or better neurological outcome². (CoSTR 2015)

The IV or IO dose is 20mcg/kg [Class A; Expert Consensus Opinion] and the ETT dose 30 mcg/kg¹ [Class A; LOE II].

Bradycardia caused by hypoxaemia should be treated with ventilation and oxygen but if unresponsive, should be treated with adrenaline (epinephrine)¹.

Severe bradycardia and or bradycardia with hypotension should be treated with adrenaline (epinephrine), not atropine.

5 Calcium

Calcium may be used as an inotropic or vasopressor but it has no place in the management of an arrhythmia unless it is caused by hyperkalaemia, hypocalcaemia, hypermagnesaemia or calcium channel blocker¹. It should not be given routinely at a cardiac arrest [Class A; Expert Consensus Opinion] and is associated with worse outcome¹.

Calcium (0.15 mmol/kg) is the antidote to hypotension caused by a calcium channel blocker. The intravenous or intraosseous dose is 0.2mL/kg of 10% calcium chloride (calcium chloride dihydrate) or approximately 0.7mL/kg of 10% calcium gluconate (calcium gluconate monohydrate)(20 mg/kg). [Class A, Expert Consensus Opinion]
6 Glucose

Hypoglycaemia may be present in paediatric critical illness [LOE IV], particularly in infants. Hyperglycaemia also occurs in paediatric critical illness and is associated with increased mortality [LOE IV] but it is not known if this is the cause. The normal level is 3-8 mmol/L.

The blood sugar level should be checked during CPR and after ROSC with the aim of ensuring normoglycaemia 4 [Class A; Expert Consensus Opinion]. Hypoglycaemia may be treated with 0.25g/kg glucose by IV or IO infusion with any hyperosmolar solution, for example, 0.5mL/kg of 50% (only via a central venous line) or 2.5mL/kg of 10%. Avoid extravasation, especially from peripheral veins, and avoid overdosage. The maintenance requirement to avoid hypoglycaemia in infancy is approximately 5-8 mg/kg/min.

7 Lidocaine (lignocaine)

Although lidocaine (lignocaine) has a membrane stabilizing effect and a potential to aid defibrillation, it may increase the defibrillation threshold. Lidocaine (lignocaine) may be used for the treatment of shock-resistant ventricular fibrillation or pulseless ventricular tachycardia2 (CoSTR 2015, weak recommendation, very low quality of evidence). When IV and IO access are impossible, lidocaine (lignocaine) may be given via endotracheal tube. The dose of lidocaine (lignocaine) is 1mg/kg IV, IO or ETT.

8 Magnesium

Hypomagnesaemia may cause life-threatening ventricular tachyarrhythmia, particularly when associated with hypokalaemia. Magnesium is the preferred antidysrrythmic treatment for polymorphic ventricular tachycardia (Torsade de pointes – “Twisting of peaks”) due to acquired or congenital prolonged QT interval syndromes 3 [Class A; LOE IV]. Neither increased ROSC nor survival in adults has been demonstrated in treatment of VF with magnesium 5 [LOE IV]. The intravenous or intraosseous bolus dose of magnesium (magnesium sulfate heptahydrate) is 0.1-0.2 mmol/kg followed by an infusion of 0.3mmol/kg over 4 hours.

9 Potassium

Hypokalaemia may cause a life-threatening tachydysrhythmia. Emergency treatment is the intravenous or intraosseous administration of 0.03 - 0.07 mmol/kg by slow injection [Class A; Expert Consensus Opinion] over several minutes. If the situation is critical but not immediately life-threatening severe hypokalaemia may be treated with an infusion of 0.2 - 0.5mmol/kg/hour to a maximum of 1mmol/kg.

Extreme caution in the use of concentrated solutions of potassium is advised. Infusions should only be given by infusion pumps and frequent (half-hourly – hourly) serum monitoring with continuous ECG display is required, preferably in an intensive care unit setting. Mistakes in the calculation of potassium requirement and inadvertent administration of potassium cause avoidable deaths. (Note that a small bolus injection may cause a dangerous rise in serum potassium: a 1 mmol bolus of potassium in a 5 kg infant theoretically raises the serum level approximately 4 mmol/L). Therapies which rapidly decrease serum potassium level are intravenous glucose + insulin, inhaled or intravenous salbutamol + intravenous glucose or a combination of these agents (insulin + glucose + salbutamol) with or
without sodium bicarbonate. Sodium bicarbonate alone is the least effective therapy [LOE III-1].

10 Procainamide

Numerous observational studies and small case series suggest that procainamide can be used to treat haemodynamically stable supraventricular tachycardia and ventricular tachycardia in children [Class B; LOE IV]. The intravenous dose is 10-15 mg/kg infused over 30-60 minutes.

11 Sodium Bicarbonate

Sodium bicarbonate has a limited and unproven place in the management of cardiorespiratory arrest and routine administration is not recommended. Administration of IV or IO sodium bicarbonate neutralizes hydrogen ions in the blood but in doing so produces carbon dioxide which may re-enter cells to exacerbate intracellular acidosis.

Other deleterious effects include hypernatraemia and hyperosmolality which may depress myocardial function. Nonetheless, administration of sodium bicarbonate may be useful in severe metabolic acidosis (pH < 7.1) or prolonged arrest. The IV or IO dose is 0.5-1 mmol/kg after adequate ventilation with oxygen and chest compression have been established [Class B; Expert Consensus Opinion].

12 Vasopressors

Adrenaline (epinephrine) or vasopressin or a combination of vasopressors may maintain cerebral blood flow and assist return of spontaneous circulation by optimizing coronary blood flow. However, it is uncertain if survival or improved neurological outcome can be attributed to use of vasopressors (CoSTR 2015).

Although vasopressin has been used in a series of paediatric case reports it has not been investigated systematically in the paediatric age group and the optimal dose is unknown. However, by extrapolation from adult experience a bolus dose would be approximately 0.5-0.8 U/kg IV or IO [Class B; Expert Consensus Opinion].

13 Fluid Therapy

If hypovolaemia is suspected as the cause of cardiorespiratory arrest, intravenous or intraosseous crystalloid may be used initially for resuscitation [Class A] as a bolus of 20mL/kg. Additional boluses or colloid solution should be titrated against the response.

References


### TABLE of DRUGS, FLUIDS, ENDOTRACHEAL TUBES and DIRECT CURRENT SHOCK FOR PAEDIATRIC RESUSCITATION

<table>
<thead>
<tr>
<th>Age</th>
<th>Body weight kg *</th>
<th>Height cm *</th>
<th>0</th>
<th>2m</th>
<th>5m</th>
<th>1y</th>
<th>2y</th>
<th>3y</th>
<th>4y</th>
<th>5y</th>
<th>6y</th>
<th>7y</th>
<th>8y</th>
<th>9y</th>
<th>10y</th>
<th>11y</th>
<th>12y</th>
<th>13y</th>
<th>14y</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>3.5</td>
<td>5</td>
<td>7</td>
<td>10</td>
<td>12</td>
<td>14</td>
<td>16</td>
<td>18</td>
<td>20</td>
<td>22</td>
<td>25</td>
<td>28</td>
<td>32</td>
<td>36</td>
<td>40</td>
<td>46</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>50</td>
<td>58</td>
<td>65</td>
<td>75</td>
<td>85</td>
<td>94</td>
<td>102</td>
<td>109</td>
<td>115</td>
<td>121</td>
<td>127</td>
<td>132</td>
<td>138</td>
<td>144</td>
<td>151</td>
<td>157</td>
<td>162</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug/Agent</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenaline (epinephrine) 1 in 1000: mL (10 mcg/kg)</td>
<td>0.035, 0.05, 0.07, 0.10, 0.12, 0.14, 0.16, 0.18, 0.2, 0.22, 0.25, 0.28, 0.32, 0.36, 0.4, 0.46, 0.5 mL</td>
</tr>
<tr>
<td>Amiodarone: mg (5 mg/kg)</td>
<td>17.5, 25, 35, 50, 60, 70, 80, 90, 100, 110, 125, 140, 160, 180, 200, 230, 250 mg</td>
</tr>
<tr>
<td>Lidocaine (lignocaine) 1%: mL (1 mg/kg)</td>
<td>0.3, 0.5, 0.7, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3.2, 3.6, 4, 4.6, 5 mL</td>
</tr>
<tr>
<td>Sodium bicarbonate 8.4%: mL (1 mmol/kg)</td>
<td>3.5, 5, 7, 10, 12, 14, 16, 18, 20, 22, 25, 28, 32, 36, 40, 46, 50 mL</td>
</tr>
<tr>
<td>Fluid volume: mL (20 mL/kg)</td>
<td>70, 100, 140, 200, 240, 280, 320, 360, 400, 440, 500, 560, 640, 720, 800, 920, 1000 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endotracheal tube</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncuffed size: Age/4 + 4 mm (2 years and above)</td>
<td>3.5, 3.5, 3.5, 4, 4.5, 4.5, 5, 5, 5.5, 5.5, 6, 6, 6.5, 6.5, 7, 7, 7.5 mm</td>
</tr>
<tr>
<td>Cuffed size: Age/4 + 3 mm</td>
<td>3.5, 3.5, 3.5, 4, 4.5, 4.5, 4.5, 5, 5, 5.5, 5.5, 6, 6, 6.5 mm</td>
</tr>
<tr>
<td>Oral length: Age/2 + 12 cm (2 years and above)</td>
<td>9.0, 11, 11.5, 12, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19 cm</td>
</tr>
<tr>
<td>Nasal length: Age/2 + 14 cm (2 years and above)</td>
<td>11, 12, 13, 14, 15, 16, 17, 18, 19, 19, 20, 20, 21, 21, 22, 22, 23 cm</td>
</tr>
</tbody>
</table>

| Direct Current shock (biphasic or monophasic) |   |
| VF, pulseless VT, First Shock (J/kg) and all subsequent shocks, unsynchronized: Joules | 10, 20, 30, 50, 50, 70, 70, 70, 100, 100, 100, 150, 150, 150, 200, 200 J |
| Pulsatile VT, synchronized (approx 2 J/kg): Joules | 5, 10, 15, 20, 20, 30, 30, 40, 40, 40, 50, 50, 70, 70, 80, 90, 100 J |
| SVT, synchronized (approx 1 J/kg): Joules | 3, 5, 7, 10, 10, 15, 15, 20, 20, 20, 30, 30, 30, 30, 50, 50 J |

* 50th percentiles